Do analysts prefer KYTX or CUE?

Kyverna Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 291.34%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer KYTX or CUE?

In the previous week, Cue Biopharma had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Kyverna Therapeutics. Cue Biopharma's average media sentiment score of 1.00 beat Kyverna Therapeutics' score of 0.88 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CABA or CUE?

Cabaletta Bio presently has a consensus price target of $15.50, suggesting a potential upside of 462.00%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CABA or CUE?

In the previous week, Cue Biopharma had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Cabaletta Bio. Cue Biopharma's average media sentiment score of 1.00 beat Cabaletta Bio's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PRTA or CUE?

Prothena currently has a consensus target price of $23.75, suggesting a potential upside of 180.20%. Given Prothena's stronger consensus rating and higher probable upside, analysts plainly believe Prothena is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRTA or CUE more profitable?

Cue Biopharma has a net margin of -59.65% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Cue Biopharma -59.65% -98.30% -53.69%

Does the media favor PRTA or CUE?

In the previous week, Prothena had 5 more articles in the media than Cue Biopharma. MarketBeat recorded 9 mentions for Prothena and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.00 beat Prothena's score of 0.53 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CUE or PRTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, CUE or PRTC?

Cue Biopharma has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cue Biopharma $27.47M 4.02 -$26.60M -$5.58 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Do analysts rate CUE or EPRX?

Eupraxia Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 173.81%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Does the media refer more to CUE or EPRX?

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 6 mentions for Eupraxia Pharmaceuticals and 4 mentions for Cue Biopharma. Eupraxia Pharmaceuticals' average media sentiment score of 1.41 beat Cue Biopharma's score of 1.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cue Biopharma (CUE) Competitors

$26.69 -0.18 (-0.67%)

As of 10:29 AM Eastern

Compare

CUE vs. KYTX, CABA, PRTA, PRTC, and EPRX

Should you buy Cue Biopharma stock or one of its competitors? MarketBeat compares Cue Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cue Biopharma include Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Prothena (PRTA), PureTech Health (PRTC), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "biotechnology" industry.

How does Cue Biopharma compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, Cue Biopharma had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Kyverna Therapeutics. Cue Biopharma's average media sentiment score of 1.00 beat Kyverna Therapeutics' score of 0.88 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kyverna Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

Kyverna Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 291.34%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kyverna Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Kyverna Therapeutics' return on equity of -81.88% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Cue Biopharma has higher revenue and earnings than Kyverna Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Cue Biopharma	$27.47M	4.02	-$26.60M	-$5.58	N/A

Summary

Kyverna Therapeutics beats Cue Biopharma on 8 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Cabaletta Bio has a beta of 3.3, meaning that its stock price is 230% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

In the previous week, Cue Biopharma had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Cabaletta Bio. Cue Biopharma's average media sentiment score of 1.00 beat Cabaletta Bio's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio presently has a consensus price target of $15.50, suggesting a potential upside of 462.00%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

35.0% of Cue Biopharma shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cabaletta Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Cue Biopharma has higher revenue and earnings than Cabaletta Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Cue Biopharma	$27.47M	4.02	-$26.60M	-$5.58	N/A

Summary

Cue Biopharma beats Cabaletta Bio on 8 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Prothena?

Prothena (NASDAQ:PRTA) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Cue Biopharma has a net margin of -59.65% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Prothena has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

In the previous week, Prothena had 5 more articles in the media than Cue Biopharma. MarketBeat recorded 9 mentions for Prothena and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.00 beat Prothena's score of 0.53 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.1% of Prothena shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prothena currently has a consensus target price of $23.75, suggesting a potential upside of 180.20%. Given Prothena's stronger consensus rating and higher probable upside, analysts plainly believe Prothena is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cue Biopharma has lower revenue, but higher earnings than Prothena. Cue Biopharma is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$57.94M	7.66	-$244.09M	-$2.82	N/A
Cue Biopharma	$27.47M	4.02	-$26.60M	-$5.58	N/A

Summary

Prothena beats Cue Biopharma on 12 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to PureTech Health?

Cue Biopharma (NASDAQ:CUE) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. PureTech Health's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
PureTech Health	N/A	N/A	N/A

Cue Biopharma has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

In the previous week, Cue Biopharma had 4 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Cue Biopharma and 0 mentions for PureTech Health. Cue Biopharma's average media sentiment score of 1.00 beat PureTech Health's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cue Biopharma	Positive
PureTech Health	Neutral

Cue Biopharma has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.02	-$26.60M	-$5.58	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Summary

Cue Biopharma beats PureTech Health on 7 of the 11 factors compared between the two stocks.

How does Cue Biopharma compare to Eupraxia Pharmaceuticals?

Cue Biopharma (NASDAQ:CUE) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Eupraxia Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 173.81%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Cue Biopharma has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.02	-$26.60M	-$5.58	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

35.0% of Cue Biopharma shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cue Biopharma has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Eupraxia Pharmaceuticals' return on equity of -87.56% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 6 mentions for Eupraxia Pharmaceuticals and 4 mentions for Cue Biopharma. Eupraxia Pharmaceuticals' average media sentiment score of 1.41 beat Cue Biopharma's score of 1.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Eupraxia Pharmaceuticals beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$115.06M	$3.55B	$6.86B	$12.43B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-4.91	7.29	280.73	24.99
Price / Sales	4.02	1,266.92	643.21	112.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.61	16.69	10.94	6.21
Net Income	-$26.60M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-13.14%	0.24%	0.78%	1.28%
1 Month Performance	-7.03%	-7.52%	-4.20%	-3.62%
1 Year Performance	-96.17%	47.22%	61.51%	18.37%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	0.4761 of 5 stars	$26.75 -0.5%	N/A	-96.0%	$111.54M	$27.47M	N/A	60	News Coverage
KYTX Kyverna Therapeutics	2.3634 of 5 stars	$7.29 -2.7%	$30.00 +311.5%	+118.3%	$442.83M	N/A	N/A	96	Upcoming Earnings
CABA Cabaletta Bio	1.6846 of 5 stars	$2.66 -2.4%	$15.50 +483.8%	+86.8%	$431.93M	N/A	N/A	50	Upcoming Earnings
PRTA Prothena	3.268 of 5 stars	$8.12 -3.4%	$23.75 +192.5%	+22.3%	$424.82M	$9.68M	N/A	130
PRTC PureTech Health	0.0088 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. KYTX, CABA, PRTA, PRTC, and EPRX

How does Cue Biopharma compare to Kyverna Therapeutics?

Summary

How does Cue Biopharma compare to Cabaletta Bio?

Summary

How does Cue Biopharma compare to Prothena?

Summary

How does Cue Biopharma compare to PureTech Health?

Summary

How does Cue Biopharma compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. KYTX, CABA, PRTA, PRTC, and EPRX

How does Cue Biopharma compare to Kyverna Therapeutics?

Does the media prefer KYTX or CUE?

Do institutionals and insiders have more ownership in KYTX or CUE?

Which has more risk & volatility, KYTX or CUE?

Do analysts prefer KYTX or CUE?

Is KYTX or CUE more profitable?

Which has higher valuation and earnings, KYTX or CUE?

Summary

How does Cue Biopharma compare to Cabaletta Bio?

Which has more risk & volatility, CABA or CUE?

Does the media favor CABA or CUE?

Do analysts prefer CABA or CUE?

Do insiders and institutionals have more ownership in CABA or CUE?

Is CABA or CUE more profitable?

Which has better earnings and valuation, CABA or CUE?

Summary

How does Cue Biopharma compare to Prothena?

Is PRTA or CUE more profitable?

Which has more volatility & risk, PRTA or CUE?

Does the media favor PRTA or CUE?

Do insiders & institutionals hold more shares of PRTA or CUE?

Do analysts rate PRTA or CUE?

Which has preferable valuation and earnings, PRTA or CUE?

Summary

How does Cue Biopharma compare to PureTech Health?

Do institutionals & insiders hold more shares of CUE or PRTC?

Do analysts rate CUE or PRTC?

Is CUE or PRTC more profitable?

Which has more risk & volatility, CUE or PRTC?

Does the media refer more to CUE or PRTC?

Which has better valuation & earnings, CUE or PRTC?

Summary

How does Cue Biopharma compare to Eupraxia Pharmaceuticals?

Do analysts rate CUE or EPRX?

Which has preferable earnings & valuation, CUE or EPRX?

Do insiders and institutionals hold more shares of CUE or EPRX?

Which has more volatility and risk, CUE or EPRX?

Is CUE or EPRX more profitable?

Does the media refer more to CUE or EPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools